<DOC>
	<DOCNO>NCT00605306</DOCNO>
	<brief_summary>This study investigate safety tolerability indacaterol maleate/mometasone furoate via Twisthaler device 14 day treatment patient mild moderate asthma .</brief_summary>
	<brief_title>Safety Tolerability Indacaterol Maleate/Mometasone Furoate Delivered Via Twisthaler® Device After 14 Days Treatment Patients With Mild Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Male female adult patient age 1865 year ( inclusive ) Patients mildmoderate asthma Forced expiratory volume one second ( FEV1 ) Visits 1 2 ≥60 % predict normal value patient . Body mass index ( BMI ) must within range 1832 kg/m^2 . Nonsmokers light smoker ( ≤10 cigarette per day ) , smoke history 10 pack year less . Patients suffer chronic obstructive pulmonary disease ( COPD ) Patients hospitalized emergency treatment asthma attack 6 month prior study start QTcF interval &gt; 450 msec men &gt; 470 msec woman Pregnant woman nurse mother Females childbearing potential , regardless whether sexually active , use reliable form contraception ( surgical contraception double barrier method ( continue least two month follow last dose ) acceptable ) . History immunocompromise , include positive human immunodeficiency virus ( HIV ) A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . History drug alcohol abuse within 12 month dose Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>spirometry</keyword>
	<keyword>lung function</keyword>
	<keyword>serum cortisol</keyword>
	<keyword>serum potassium</keyword>
	<keyword>plasma glucose</keyword>
</DOC>